In Depth 10 Apr 2024
Silencing genes to cure diseases: an in-depth look at siRNA
Delve into the promissing and dynamic sector of siRNA technology, with new drug approvals and advancements in delivery methods.
RNA technology
- Latest Posts
In Depth 12 Feb 2024
RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing?
Find out all about about RNA editing, as two candidates have just managed to reach the clinic for the first time.
Best in Biotech 30 Jan 2024
Navigating German biotech: 13 key players to know
The German biotech ecosystem is well established despite the challenges it is facing. Discover thirteen key Germany-based biotech companies.
In Depth 25 Jan 2024
The trends that will shape the biotech industry in 2024
What does 2024 hold for the biotech industry? Delve into the experts’ insight on the biotech trends that will shape 2024.
Best in Biotech 16 Jan 2024
Five biotech companies taking Florida by storm
Check out five of the top Florida companies taking the state’s biotech industry by storm with their innovative technologies.
Podcast 6 Oct 2023
Beyond Biotech podcast 66 – treating rare diseases with tRNA
Compared to the smallest mRNA molecule, which is 300 nucleotides long, the largest transfer RNAs (tRNA) is less than a third of the size at 76 nucleotides. Scientists at Alltrna are harnessing the unique biology of tRNAs to engineer a single tRNA medicine that could treat thousands of rare diseases that share the same genetic […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 25 Jul 2023
Roche and Alnylam to work on RNAi therapeutic to treat hypertension
Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […]
News and Trends 18 Jul 2023
Korro Bio and Frequency Therapeutics to merge
Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to […]
In Depth 10 Jul 2023
“Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing
By Ashish Dhir, PhD and Amy Walker, PhD, 4basebio The pace, efficacy and scalability with which the success of mRNA vaccines against COVID-19 was demonstrated opened endless possibilities for mRNA medicine in broad areas of infectious diseases, cancers, protein-encoding replacement therapies. The advantages of RNA medicine are obvious, with the ease and speed of design […]
News and Trends 16 Jun 2023
Flamingo Therapeutics receives €1.7M to advance RNA-targeting oncology portfolio
Flamingo Therapeutics has been awarded a research grant of €1.7 million ($1.9 million) by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million ($3.2 million) project. Funding from the grant will be used to advance Flamingo Therapeutics’ RNA-targeting oncology portfolio, including translational research for its lead clinical program, […]
News and Trends 23 May 2023
FDA approval for Rznomics’ glioblastoma treatment trial
Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models and submitted the IND for […]
News and Trends 16 May 2023
SiSaf siRNA therapy gets FDA designations to treat autosomal dominant osteopetrosis
SiSaf Ltd, an RNA delivery and therapeutics company, has announced that SIS-101-ADO, its siRNA therapeutic for patients with autosomal dominant osteopetrosis Type 2 (ADO2), has been granted orphan drug designation by the U.S. FDA. Also, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted rare pediatric disease designation […]
ADVERTISEMENT